Clinical Trial Update: Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of an anti-PD-L1 therapy in stage IIIA(N2) non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• anti-PD-L1 inhibitor

Snippet

Sponsor: Swiss Cancer Institute | Conditions: NSCLC Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-10-28